ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
6,025.99
-0.95%
US Tech 100
20,874.00
-1.46%
Dow Jones
44,303.40
-0.99%
Brent Oil
74.565
0.00%
Bitcoin
96,888.76
0.44%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. UK
  5. LSE

  6. Vivoryon Therapeutics Nv (0R3M) Quote

Vivoryon Therapeutics Nv

Vivoryon Therapeutics Nv (0R3M)

LSE
4.71
0.00
(0.00%)
Closed February 09 11:30AM
Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
4.71
Bid
0.00
Ask
0.00
Volume
322
0.00 Day's Range 0.00
4.71 52 Week Range 4.71
Market Cap
-
Previous Close
4.71
Open
-
Last Trade
7
@
1.942
(O)
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
3,933
Shares Outstanding
0.00
Dividend Yield
-
PE Ratio
0.00
Earnings Per Share (EPS)
-
Revenue
-3.62M
Net Profit
-28.34M

About Vivoryon Therapeutics Nv

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
www.vivoryon.com
Headquarters
Halle, Deu
Founded
-
Vivoryon Therapeutics Nv is listed in the Biological Pds,ex Diagnstics sector of the London Stock Exchange with ticker 0R3M. The last closing price for Vivoryon Therapeutics Nv was 4.71 €. Over the last year, Vivoryon Therapeutics Nv shares have traded in a share price range of 4.71 € to 4.71 €.

Vivoryon Therapeutics Nv currently has 0 shares outstanding.

Ask ADVFN Intelligence (AI)

0R3M Latest News

More News

Vivoryon Therapeutics N.V. Presents Topline Phase 2 Data from VIVA-MIND Strongly Supporting Varoglutamstat’s Potential to Improve Kidney Function

Vivoryon Therapeutics N.V. Presents Topline Phase 2 Data from VIVA-MIND Strongly Supporting Varoglutamstat’s Potential to Improve Kidney Function Vivoryon Therapeutics N.V. Presents Topline Phase...

December 09 2024
UK Regulatory

Vivoryon Therapeutics N.V. to Report Q3 2024 Financial Results and Operational Progress on December 10, 2024

Vivoryon Therapeutics N.V. to Report Q3 2024 Financial Results and Operational Progress on December 10, 2024 Vivoryon Therapeutics N.V. to Report Q3 2024 Financial Results and Operational Progress...

December 04 2024
UK Regulatory

Vivoryon Therapeutics N.V. Presents Outstanding Phase 2b Results of Varoglutamstat on Kidney Function at ASN Kidney Week 2024

Vivoryon Therapeutics N.V. Presents Outstanding Phase 2b Results of Varoglutamstat on Kidney Function at ASN Kidney Week 2024 Vivoryon Therapeutics N.V. Presents Outstanding Phase 2b Results of...

October 26 2024
UK Regulatory

Vivoryon Therapeutics N.V. Announces Late-breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024

Vivoryon Therapeutics N.V. Announces Late-breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024 Halle (Saale) / Munich, Germany, October 11, 2024 – Vivoryon...

October 11 2024
UK Regulatory

Vivoryon Therapeutics N.V. Shares Highlights from Virtual Kidney Disease KOL Event

Vivoryon Therapeutics N.V. Shares Highlights from Virtual Kidney Disease KOL Event Halle (Saale) / Munich, Germany, October 1, 2024 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY;...

October 01 2024
UK Regulatory

Vivoryon Therapeutics N.V. Reports H1 2024 Progress Marked by Compelling Kidney Function Data and Execution of Strategy to Advance Varoglutamstat in Kidney Disease

Vivoryon Therapeutics N.V. Reports H1 2024 Progress Marked by Compelling Kidney Function Data and Execution of Strategy to Advance Varoglutamstat in Kidney Disease Vivoryon Therapeutics N.V...

September 12 2024
UK Regulatory

Vivoryon Therapeutics N.V. Announces Completion of Share Capital Reduction and Change to Articles of Association

Vivoryon Therapeutics N.V. Announces Completion of Share Capital Reduction and Change to Articles of Association Vivoryon Therapeutics N.V. Announces Completion of Share Capital Reduction and...

September 05 2024
UK Regulatory

Vivoryon Therapeutics N.V. to Report Half Year 2024 Financial Results on September 12, and to Host KOL Event on September 30, 2024

Vivoryon Therapeutics N.V. to Report Half Year 2024 Financial Results on September 12, and to Host KOL Event on September 30, 2024 Vivoryon Therapeutics N.V. to Report Half Year 2024 Financial...

September 05 2024
UK Regulatory

Vivoryon Therapeutics N.V. Announces New Data Showing Unique Treatment Effects of Varoglutamstat on Kidney Function in Patients with Diabetes and Outlines Proposed Clinical Development Plan in Diabetic Kidney Disease

Vivoryon Therapeutics N.V. Announces New Data Showing Unique Treatment Effects of Varoglutamstat on Kidney Function in Patients with Diabetes and Outlines Proposed Clinical Development Plan in...

July 18 2024
UK Regulatory

Vivoryon Therapeutics N.V. to Host R&D Update Call on July 18, 2024 Focused on Progress in Kidney Disease

Vivoryon Therapeutics N.V. to Host R&D Update Call on July 18, 2024 Focused on Progress in Kidney Disease Vivoryon Therapeutics N.V. to Host R&D Update Call on July 18, 2024 Focused on...

July 09 2024
UK Regulatory
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1004.714.714.71944.71DE
4004.714.714.714514.71DE
12004.714.714.7139334.71DE
26004.714.714.7136904.71DE
52004.714.714.71121844.71DE
156004.714.714.7159874.71DE
260004.714.714.7142974.71DE

0R3M - Frequently Asked Questions (FAQ)

What is the current Vivoryon Therapeutics Nv share price?
The current share price of Vivoryon Therapeutics Nv is 4.71 €
What is the 1 year trading range for Vivoryon Therapeutics Nv share price?
Vivoryon Therapeutics Nv has traded in the range of 4.71 € to 4.71 € during the past year
What is the reporting currency for Vivoryon Therapeutics Nv?
Vivoryon Therapeutics Nv reports financial results in EUR
What is the latest annual turnover for Vivoryon Therapeutics Nv?
The latest annual turnover of Vivoryon Therapeutics Nv is EUR -3.62M
What is the latest annual profit for Vivoryon Therapeutics Nv?
The latest annual profit of Vivoryon Therapeutics Nv is EUR -28.34M
What is the registered address of Vivoryon Therapeutics Nv?
The registered address for Vivoryon Therapeutics Nv is WEINBERGWEG 22, HALLE, 06120
What is the Vivoryon Therapeutics Nv website address?
The website address for Vivoryon Therapeutics Nv is www.vivoryon.com
Which industry sector does Vivoryon Therapeutics Nv operate in?
Vivoryon Therapeutics Nv operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
ASTAscent Resources Plc
1.90p
(100.00%)
591.55k
NTQEnteq Technologies Plc
2.85p
(58.33%)
17.97M
THRUThruvision Group Plc
3.25p
(30.00%)
307.66k
IMMImmupharma Plc
4.98p
(27.69%)
14.75M
GEXGeorgina Energy Plc
6.375p
(24.39%)
5.16M
BELLBelluscura Plc
1.875p
(-71.15%)
13.68M
APQApq Global Limited
2.00p
(-69.23%)
60.87k
IOMIomart Group Plc
45.40p
(-23.57%)
1.76M
SYMESupply@me Capital Plc
0.002p
(-20.00%)
736.23M
PRMProteome Sciences Plc
3.50p
(-17.45%)
50.06k
SYMESupply@me Capital Plc
0.002p
(-20.00%)
736.23M
ORCPOracle Power Plc
0.017p
(-14.14%)
523.64M
CPAICapai Plc
0.0475p
(7.95%)
355.25M
NTVONativo Resources Plc
0.0017p
(0.00%)
347.62M
MSMNMosman Oil And Gas Limited
0.04p
(2.56%)
263.67M

Discussion

View Full Feed
capgain capgain 4 minutes ago
Billy Strings and Bryan Sutton

https://www.youtube.com/watch?v=K6eGnZEoHC8
capgain capgain 7 minutes ago
Love it, Bull. The future is looking brighter.
Seminole Red Seminole Red 10 minutes ago
Duffy: I Think We Have Generals Using Helicopters as ‘Personal Ubers’, That’s Wasteful and Dangerous

https://www.breitbart.com/politics/2025/02/07/duffy-i-think-we-have-generals-using-helicopters-as-personal-ubers-thats-wasteful-and-dangerous/?utm_source=facebook&utm_medium=social&fbc
Bull_Dolphin Bull_Dolphin 10 minutes ago
Gov torture of disabled vet:

https://x.com/OKPrayinPatriot/status/1887928623295803472
LVerstee LVerstee 12 minutes ago
A perfect description of yourself. Couldn't be more to the point.

But there is one thing I have learned through the years. Which is that the so-called "critics" out there will never be satisfied no matter how much evidence you shove down their throats.

These people wil
ITUP
FUNYMUNY FUNYMUNY 13 minutes ago
They will just keep milking the sheep that buy into this failure. They have NOTHING but shares to sell. Buyer beware
PPCBD
SEV123 SEV123 14 minutes ago
And yet my friend, once again you refuse to answer what's more important. You said something was coming but you've made promises in the past as Future and as Silicon and nothing has ever come of it.
SEV
Idiot Mayor Idiot Mayor 18 minutes ago
FIVE…… FIVE MORE DAYS!!! On Friday, you will either be vindicated or you will be buried. On Monday you will either be broke and FRANTICALLY seeking a new, plausible explanation to keep the desperate hope alive or you will be counting your billions as the naked shorts scramble to cover this up to dol
DBMM
Bob Mullet Bob Mullet 29 minutes ago
Still posting the Boiler Room party line?

People laugh at you 🤦🏻‍♂️ 

Keep it up!!?!
KBLB
Bull_Dolphin Bull_Dolphin 29 minutes ago
Good morning Larry, another great day!
Bull_Dolphin Bull_Dolphin 30 minutes ago
Stephen Miller goes off:

https://x.com/JackPosobiec/status/1887970744526569638
SkeBallLarry SkeBallLarry 32 minutes ago
" a Brilliant move ~ Good Sabbath Morn', Bull "
vator vator 58 minutes ago
style="caret-color: rgb(0, 29, 53); color: rgba(0, 29, 53, 1); font-family: "Google Sans", Roboto, "Helvetica Neue", sans-serif; font-size: 18px"an estimated 704,000 new cancer cases are expected in Brazil eac
NWBO
thecrusher2011 thecrusher2011 2 hours ago
Oh now you've hurt my feelings. Not trying to brag or anything but I'll have you know I went to Tijuana once
marcis marcis 2 hours ago
This is exactly your motivation here.
500 million borrowed ( short ) shares, sell two tick down to .0006 is already is a fast $100,000

Down to 4 or 5 you get a big bonus plus

No wonder the passion to be on your point all weekend and night

I say t
RDAR
Testpilot Testpilot 2 hours ago
I see that sales only dropped by .46%, however the operating income, Net income from continuing operation before income tax, along with Net income fell by -22.99%, -88.36%, and -94.40% respectively. The company submitted a vague explanation "Recognizing subsidiary equity loss and impairment" as to
CRTG
nshi2 nshi2 2 hours ago
https://youtu.be/2xE4bopeXhw
LWLG
thecrusher2011 thecrusher2011 2 hours ago
😂😂😂😂 you're still mad that I noticed all liberals are feminine
Louinjaxxx Louinjaxxx 2 hours ago
A friend of mine wrote a book on TA (Technical Analysis).  It was his opinion, and I agree with him, that TA and charting is worthless when dealing with penny stocks and especially with sub-penny stocks.
AXXA
LVerstee LVerstee 2 hours ago
I’ll wait. You either missed it or chose not to acknowledge it. Your insults don’t affect me, and I won’t take any satisfaction when you eventually understand what I mean. Not with you.
You showed one half of the evidence and you can't even tell yourself.
All you’ve proven is that you
ITUP
DMC8 DMC8 2 hours ago
https://www.sciencedirect.com/science/article/pii/S104366182500060X
AMRN
jeunke22 jeunke22 2 hours ago
One would imagine these guys have business plans in place and are aware of the critical success factors. I guess Deep Seek was a wake up call to keep an eye on capex, costs , power and sustainability.
For me Lightwave’s value propositions are becoming more solid going forward. Enjoy the Super
LWLG

Your Recent History

LSE
0R3M
Vivoryon Therapeutics Nv
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads